J 2017

Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed

FIALA, O., P. HOSEK, M. PESEK, J. FINEK, J. RACEK et. al.

Basic information

Original name

Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed

Authors

FIALA, O. (203 Czech Republic), P. HOSEK (203 Czech Republic), M. PESEK (203 Czech Republic), J. FINEK (203 Czech Republic), J. RACEK (203 Czech Republic), T. BUCHLER (203 Czech Republic), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Karel HEJDUK (203 Czech Republic, guarantor, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), O. SOREJS (203 Czech Republic), M. ECKSTEINOVA (203 Czech Republic), M. VITOVEC (203 Czech Republic), K. CIZKOVA (203 Czech Republic), R. KUCERA (203 Czech Republic) and O. TOPOLCAN (203 Czech Republic)

Edition

Neoplasma, Bratislava, Slovenská akademie vied, 2017, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.696

RIV identification code

RIV/00216224:14110/17:00097428

Organization unit

Faculty of Medicine

DOI

UT WoS

000407539900016

Keywords in English

C-reactive protein; lung cancer; NSCLC; chemotherapy; pemetrexed; prognosis

Tags

Tags

International impact, Reviewed
Změněno: 20/3/2018 14:03, Soňa Böhmová

Abstract

V originále

Pemetrexed is an intravenously administered antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC). It has been previously demonstrated that the superiority of pemetrexed is limited to patients with non-squamous histology. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in a large cohort of patients with non-squamous NSCLC treated with pemetrexed. Clinical data of 325 patients were analysed. Serum samples were collected within one week before the initiation of treatment. The median progression-free (PFS) and overall survival (OS) for patients with high CRP was 2.1 and 9.5 compared to 4.2 and 20.5 months for those with normal CRP (p=0.002 and p<0.001, respectively). The multivariable Cox proportional hazards model revealed that serum CRP (HR=1.46, p=0.002) was significantly associated with PFS and also with OS (HR=1.95, p<0.001). In conclusion, the study results suggest that pretreatment serum CRP is associated with poor outcome of non-squamous NSCLC patients treated with pemetrexed.